Ningmei Haowei Secures Tens of Millions in Angel Funding to Advance 'Cell + Gene' Precision Medicine

Beijing Ningmeihao Weisheng Technology Co., Ltd. (hereinafter referred to as “Ningmeihao Weisheng”) recently announced the completion of a tens-of-millions-yuan angel financing round. The proceeds from this round will be used to advance R&D and industrialization in the field of gene-edited cell therapies, support clinical applications in precision anti-aging and the treatment of chronic diseases such as diabetes, and drive innovative breakthroughs in the clinical application of “cell + gene” technologies.

Ningmei Haowei was founded in 2015. Leveraging cutting-edge life science technologies, the company is dedicated to providing customers with precise medical and health management solutions covering the entire lifecycle, from disease prevention and diagnosis to treatment. The founding team comprises top-tier domestic and international experts in life sciences and clinical medicine, who have been deeply engaged in cell research and gene therapy for over a decade, achieving numerous breakthrough scientific results.

Ningmeihao Weisheng leverages the dual-core drive of “cells + genes” to build a precision medicine ecosystem covering the entire life cycle:

Precision Anti-Aging:Leveraging a globally leading platform for cell technology research and industrialization, we provide personalized anti-aging solutions by offering services such as cell preparation and immune cell storage.

Chronic Disease Treatment:Actively promote the application of stem cell therapy in the treatment of major chronic diseases, including diabetes, cardiovascular diseases, and neurological disorders, and collaborate with clinical institutions to conduct efficacy evaluations, ensuring the safety and durability of treatments.

Tumor Therapy:Focusing on gene reprogramming cell technology, we have established a comprehensive tumor cell therapy system that encompasses the creation of personalized cell banks, the preparation of immune cells and stem cell differentiation, and the development of genetically engineered cell lines through gene modification. Furthermore, by leveraging the targeting specificity and cytotoxic potency of immune cells, we are developing ultra-high-purity natural killer (NK) cell products and pluripotent stem cell products, thereby providing new therapeutic avenues for cancer treatment.

Ningmeihao Weisheng provides professional immune cell cryopreservation services. Utilizing an ultra-low temperature vapor-phase liquid nitrogen environment at -196°C and advanced technologies to ensure cell viability, the stored youthful and vital cells can be widely applied in disease treatment, anti-aging, and healthcare.

In the field of cell preparation, Beijing Ningmeihao Weisheng Technology Co., Ltd. possesses advanced technologies for stem cell and NK cell preparation, strictly adhering to pharmaceutical-grade cell production systems and quality management standards to ensure the safety and efficacy of its cell products. Furthermore, the company has established a comprehensive clinical efficacy evaluation system for cell therapy, employing multi-dimensional assessments to guarantee treatment outcomes and patient safety.

Stem cells, a class of cells with self-renewal and multidirectional differentiation potential, are hailed by the medical community as “universal cells” and hold immense potential in disease treatment and tissue repair.

It is reported that the global number of people with diabetes has exceeded 537 million (IDF 2023 data). Traditional therapies have long relied on insulin replacement treatment, which cannot reverse the failure of pancreatic β-cell function. Relying on its independently developed dual-technology platform of “directed differentiation of pluripotent stem cells + gene editing,” Beijing Ningmeihao Weisheng Technology Co., Ltd. is exploring therapeutic solutions that utilize stem cell therapy to repair damaged pancreatic islet cells and restore insulin secretory function. This approach holds promise for addressing the root cause of the disease, bringing new hope to patients with diabetes.

Ningmeihao Weisheng maintains a rigorous quality control system. Its cell sources are safe, with low immunogenicity and no risk of potential infectious diseases or carcinogenesis. Cells are stored at nationally accredited institutions using world-class storage equipment to ensure long-term safety, enabling lifelong utility from a single storage event. The company is equipped with GMP-compliant independent pharmaceutical-grade laboratories, featuring top-tier global R&D, production, and quality inspection equipment, sterile operational environments, and automated, closed-loop cell culture systems. Furthermore, Ningmeihao Weisheng has established a clinical efficacy evaluation framework for cell therapy, comprehensively assessing efficacy, safety, durability, and patient response through multi-dimensional indicators such as cytotoxicity, target antigen recognition capability, and multi-cytokine secretion capacity.

Beijing Ningmeihao Weisheng Technology Co., Ltd. is committed to delivering more scientific and precise solutions for human health and longevity through its dual-enabling model of “cells + genes.” This round of financing will inject strong momentum into the company’s R&D in cell therapy and gene editing technologies, accelerating the translation of innovative therapies from laboratory research to clinical application.

In its future development plans, Beijing Ningmeihao Weisheng Technology Co., Ltd. will focus on expanding the application scenarios of stem cell therapy in precision anti-aging and chronic disease treatment, continue to deepen its presence in the precision medicine sector, fully promote the industrialization of cell therapy technologies, and contribute to the advancement of global healthcare.

Beijing Ningmeihao Weiwei Biomedical Technology Co., Ltd. (hereinafter referred to as “Ningmeihao Weiwei”) is a precision medicine enterprise centered on “cell + gene” technologies, dedicated to providing innovative solutions for health management across the entire life cycle. The company’s business spans stem cell therapy, immune cell storage, genetic diagnostics, and precise intervention for chronic diseases, establishing a closed-loop industrial chain encompassing “R&D, production, clinical application, and services.” Ningmeihao Weiwei strives to empower patients with personalized and precise treatment regimens through the dual advantages of cellular reprogramming and genomic decoding.